Innovative approaches to obesity treatment are emerging, including Syntis Bio’s novel intestinal coating technology mimicking gastric bypass effects, funded with $38 million to advance clinical development. Chinese pharma Innovent Biologics received approval for mazdutide, a dual glucagon/GLP-1 receptor agonist producing significant weight loss in trials. Additionally, Protagonist Therapeutics introduced a 'triple-G' obesity pill showing promising preclinical results. These developments mark diversification and intensification of obesity pharmacotherapy pipelines globally.